Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI Dupixent significantly reduced itch and hive activity from baseline; 41% of patients ...

Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare Sanofi and CD&R enter exclusive negotiations to transfer a 50% controlling stake in Opella with Sanofi to remain ...

Sanofi and Orano join forces to develop next-generation radioligand medicines Paris, . Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development ...

Third quarter 2024 results were reviewed by management during a conference call with the financial community. The presentation was followed by a Q&A session. Friday October 25, 2024 14:00 - 15:30 CET ...

At Sanofi, we’re proud to be premium partner of Paris 2024. Like Olympians and Paralympians, we spend every day challenging ourselves and each other to be better, go further, and to never, ever settle ...

Our manufacturing sites are state-of-the-art, powered by big data and digital. It is by producing vaccines that our mission takes on its full meaning. It is the bridge between scientific advances and ...

Sanofi US (Sanofi-Aventis U.S. LLC and Sanofi US Services Inc.) respects the interest that visitors to our websites have in understanding what information is collected electronically, how it is ...

We want to improve the lives of millions of people who don’t have access to the help they need. To do that, we’re expanding our health-system partnerships at local, regional, and global levels.

Mission: to design our clinical trials to be inclusive and more representative of the populations who are most likely to benefit from our medicines. Vision: we envision a future where inclusivity is ...